On August 30th, Ganglonghui announced its interim performance. For the six months ended June 30, 2024, the group's revenue increased by 1.7 million yuan to 44.8 million yuan, compared with 43.1 million yuan for the six months ended June 30, 2023. This was mainly due to the company's original plan to strategically focus on rare diseases in 2021, and He Li'an's transition arrangement for distribution in Hong Kong was completed in the second half of 2023. In addition to He Li'an's sales in Hong Kong, the group's revenue increased by 8.8 million yuan or 24.4% compared to the same period in 2023, mainly due to the increase in sales of Mairui Bei. The group's gross profit increased by 2.7 million yuan to 29.4 million yuan from 26.7 million yuan for the six months ended June 30, 2023, with a gross margin of 65.7% (2023: 62.0%). The group's R&D expenses increased by 30.3 million yuan to 1.733 billion yuan from 0.143 billion yuan for the six months ended June 30, 2023. This cost is mainly attributed to the ongoing registration trial of CAN103.

In terms of production, the group has obtained production capacity for selected licensed introduction projects, including capacity from Wuxi Bio, GC Pharma, and Mirum, among other third-party partners. The group aims to balance cost-effectiveness and quality control of drug products and/or candidate drugs. To promote the group's gene therapy product line, the group is exploring production strategies for gene therapy to help achieve high quality and capital efficiency, and is expected to further develop the group's gene therapy products through CDMO.

In terms of commercialization, with multiple products approved for sale in various regions, the group has established major operating centers in Beijing and Shanghai, as well as offices in other regions of Greater China. The group has established commercialization teams for marketed products and late-stage candidate drugs, which can rapidly expand based on the group's business growth, including market and sales, medical affairs, patient advocacy and services, and market access as the main functions, aiming to execute medical projects with key opinion leaders (KOL), enhance community awareness, and explore industry insights that contribute to drug development and market strategy. The management will continue to focus on the market and develop cost-effective strategies for the commercialization of upcoming product lines.